Iron Chelation Therapy — Deferiprone

Why Deferiprone Is Unique

Deferiprone (DFP, Ferriprox) is the only clinically available iron chelator that crosses the blood-brain barrier. Other chelators (deferoxamine, deferasirox) are too large or insufficiently lipophilic.

flowchart TD
    A["Brain Iron Excess Confirmed"] --> B{"Condition?"}

    B -- NBIA / PKAN --> C["Deferiprone Evidence Positive"]
    C --> D["MRI Iron Reduction"]
    D --> E["Motor Stabilisation"]

    B -- Parkinson Disease --> F["Deferiprone Evidence Positive"]
    F --> G["Caudate and Dentate Iron Reduced"]
    G --> H["Motor Trend Improvement"]

    B -- Alzheimer Disease --> I["Deferiprone Trial Negative"]
    I --> J["Accelerated Cognitive Decline"]
    J --> K["Essential Iron May Be Depleted"]

    B -- HFE Compound Het --> L["Phlebotomy First-Line"]
    L --> M{"Brain Symptoms Persist?"}
    M -- Yes --> N["Consider Brain Imaging - QSM"]
    N --> O{"Brain Iron Excess on MRI?"}
    O -- Yes --> P["Deferiprone - Specialist Only"]
    O -- No --> Q["Continue Phlebotomy and Antioxidants"]
    M -- No --> Q

    classDef positive fill:#58d68d,stroke:#1e8449,color:#0a1f12
    classDef negative fill:#f1948a,stroke:#c0392b,color:#1a0505
    classDef decision fill:#85c1e9,stroke:#2471a3,color:#0a1929
    classDef firstline fill:#58d68d,stroke:#1e8449,color:#0a1f12
    classDef caution fill:#f7dc6f,stroke:#b7950b,color:#1a1400

    class C,D,E,F,G,H positive
    class I,J,K negative
    class A,B,M,O decision
    class L,Q firstline
    class N,P caution

Clinical Trial Evidence

Parkinson's Disease

Devos D et al. "Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson's disease." Sci Rep. 2017;7:1398. PMC5431100

NBIA (Neurodegeneration with Brain Iron Accumulation)

Forni GL et al. "A pilot trial of deferiprone for neurodegeneration with brain iron accumulation." Haematologica. 2011;96(7):1054-1057. PMC3208690

Zorzi G et al. "Efficacy and safety of deferiprone for PKAN and NBIA: results from a four years follow-up." Parkinsonism Relat Disord. 2014. PMID: 24661465

Friedreich's Ataxia

Deferiprone (30 mg/kg/day) reduced iron accumulation in dentate nuclei after 6 months

Alzheimer's Disease — A Cautionary Note

Deferiprone AD trial results (AAIC 2024)

Neuroprotective Mechanisms Beyond Iron Removal

Molina-Holgado F et al. "Characterization of the neuroprotective potential of derivatives of the iron chelating drug deferiprone." Neurochem Res. 2015;40(3):609-620. PMID: 25559767

de Lima MNM et al. "Iron chelator deferiprone rescues memory deficits, hippocampal BDNF levels and antioxidant defenses in an experimental model of memory impairment." Biometals. 2019;32:587-597. DOI: 10.1007/s10534-018-0135-1

Safety Considerations

Relevance to Neurodevelopmental Conditions

No clinical trials of deferiprone exist for ADHD, autism, OCD, or trichotillomania. However:

  1. The mechanism is sound: brain iron excess drives oxidative stress, glutamate dysregulation, and ferroptosis in these conditions
  2. The AD trial failure suggests caution: neurodevelopmental brains may need iron for ongoing myelination and neurotransmitter synthesis
  3. Lower doses might remove toxic excess without depleting functional iron
  4. Combination with antioxidants (e.g., NAC, sulforaphane) might allow lower chelator doses
  5. For HFE carriers specifically, phlebotomy to reduce systemic iron may be safer and more appropriate than brain chelation
  6. Brain iron imaging (QSM/T2*) would be needed to demonstrate brain iron excess before chelation could be justified

Practical Position

For now, phlebotomy remains the primary iron reduction strategy for HFE carriers. Deferiprone is reserved for:

Cross-References